Optimal synthetic glycosylation of a therapeutic antibody

Journal article

Glycosylation patterns in antibodies critically determine biological and physical properties but their precise control is a significant challenge in biology and biotechnology. We describe herein the optimization of an endoglycosidase-catalyzed glycosylation of the best-selling biotherapeutic Herceptin, an anti-HER2 antibody. Precise MS analysis of the intact four-chain Ab heteromultimer reveals nonspecific, non-enzymatic reactions (glycation), which are not detected under standard denaturing conditions. This competing reaction, which has hitherto been underestimated as a source of side products, can now be minimized. Optimization allowed access to the purest natural form of Herceptin to date (≥90 %). Moreover, through the use of a small library of sugars containing non-natural functional groups, Ab variants containing defined numbers of selectively addressable chemical tags (reaction handles at Sia C1) in specific positions (for attachment of cargo molecules or "glycorandomization") were readily generated.

Authors: Parsons, T; Struwe, W; Gault, J; Yamamoto, K; Taylor, T

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Wiley
• Journal: Angewandte Chemie International Edition
• Volume: 55
• Issue: 7
• Pages: 2361-2367
• Publication date: 2016-01-12
• Acceptance date: 2015-12-02
• DOI: 10.1002/anie.201508723
• EISSN: 1521-3773
• ISSN: 1433-7851
• Language: English
• Keywords: antibodies; FFR; glycoengineering; glycosylation; native mass spectrometry; endoglycosidases